Vertex Pharmaceuticals Incorporated
VRTX
$424.99
-$4.61-1.07%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -124.60% | -114.80% | -113.83% | -114.56% | 23.31% |
| Total Depreciation and Amortization | -3.96% | 7.37% | 29.37% | 26.72% | 21.83% |
| Total Amortization of Deferred Charges | 113.56% | 113.56% | -- | -- | -- |
| Total Other Non-Cash Items | 18,338.46% | 16,595.24% | -21.39% | -42.81% | -97.40% |
| Change in Net Operating Assets | -231.49% | -93.75% | -264.52% | -303.66% | -153.72% |
| Cash from Operations | -124.86% | -113.93% | -119.23% | -123.20% | -3.18% |
| Capital Expenditure | -19.10% | -48.55% | -49.63% | -24.59% | -23.74% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 55.89% | -18.05% | -87.60% | -81.02% | -98.07% |
| Cash from Investing | 50.95% | -20.00% | -84.39% | -53.63% | -63.74% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 54.32% | 25.17% | -2.31% | 38.40% | 42.91% |
| Issuance of Common Stock | -16.68% | -14.86% | -9.37% | -16.96% | -17.69% |
| Repurchase of Common Stock | -166.20% | -142.02% | -160.31% | -185.74% | -103.16% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -16.67% | 244.44% | 322.22% | 700.00% | 2,200.00% |
| Cash from Financing | -190.85% | -165.90% | -204.18% | -236.55% | -134.08% |
| Foreign Exchange rate Adjustments | 600.00% | -258.36% | -20.35% | -153.66% | 93.81% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -3,453.09% | -4,051.83% | -402.56% | -483.80% | -107.46% |